The Combination of the PARP Inhibitor Olaparib and the ATR Inhibitor VE-821 Selectively Targets ATM-Deficient Lung Cancer Cells

被引：0
|
作者：
Jette, N. [1 ]
Radhamani, S. [1 ]
Arthur, G. [1 ]
Ye, R. [1 ]
Goutam, S. [1 ]
Boylos, A. [1 ]
Petersen, L. [1 ]
Bose, P. [1 ]
Bebb, G. [1 ]
Lees-Miller, S. [1 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Olaparib; VE-821; ATM;
D O I：
10.1016/j.jtho.2019.08.1192
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-41
引用
收藏
页码：S570 / S571
页数：2
相关论文
共 50 条
  • [41] Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
    Osoegawa, Atsushi
    Gills, Joell J.
    Kawabata, Shigeru
    Dennis, Phillip A.
    ONCOTARGET, 2017, 8 (50) : 87044 - 87053
  • [42] The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
    Lallo, Alice
    Frese, Kristopher K.
    Morrow, Christopher J.
    Sloane, Robert
    Gulati, Sakshi
    Schenk, Maximillian W.
    Trapani, Francesca
    Simms, Nicole
    Galvin, Melanie
    Brown, Stewart
    Hodgkinson, Cassandra L.
    Priest, Lynsey
    Hughes, Adina
    Lai, Zhongwu
    Cadogan, Elaine
    Khandelwal, Garima
    Simpson, Kathryn L.
    Miller, Crispin
    Blackhall, Fiona
    O'Connor, Mark J.
    Dive, Caroline
    CLINICAL CANCER RESEARCH, 2018, 24 (20) : 5153 - 5164
  • [43] PRECLINICAL STUDIES OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IMATINIB IN BRCA STRATIFIED OVARIAN CANCER
    Matheson, E.
    Salehan, M.
    Mukhopadhyay, A.
    Curtin, N. J.
    Drew, Y.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 673 - 673
  • [44] PARP inhibitor olaparib induced differential protein expression in cervical cancer cells
    Rajawat, Jyotika
    Awasthi, Poorwa
    Banerjee, Monisha
    JOURNAL OF PROTEOMICS, 2023, 275
  • [45] XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
    Ali, Reem
    Alblihy, Adel
    Toss, Michael S.
    Algethami, Mashael
    Al Sunni, Rabab
    Green, Andrew R.
    Rakha, Emad A.
    Madhusudan, Srinivasan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [46] Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
    Ivy, S. Percy
    Liu, Joyce F.
    Lee, Jung-Min
    Matulonis, Ursula A.
    Kohn, Elise C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (05) : 597 - 611
  • [47] Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents
    Cui, Yuxia
    Palii, Stela S.
    Innes, Cynthia L.
    Paules, Richard S.
    CELL CYCLE, 2014, 13 (22) : 3541 - 3550
  • [48] ATR targeting by the novel inhibitor VE-822 selectively sensitizes pancreatic cancer cells and tumors to radiation and chemoradiation
    Fokas, E.
    Prevo, R.
    Pollard, J. R.
    Reaper, P. M.
    Charlton, P.
    Cornelissen, B.
    Vallis, K.
    Hammond, E. M.
    Olcina, M. M.
    McKenna, W. G.
    Muschel, R. J.
    Brunner, T. B.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 : 41 - 41
  • [49] The Nampt inhibitor MPC-9528 and the PARP inhibitor olaparib synergize in killing a BRCA-deficient cancer cell line
    Terry-Lorenzo, R. T.
    Fleischer, T. C.
    Lockman, J. W.
    Boniface, J. J.
    Willardsen, J. A.
    Carlson, R. O.
    EJC SUPPLEMENTS, 2010, 8 (07): : 4 - 5
  • [50] Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
    Tutt, A.
    Robson, M.
    Garber, J. E.
    Domchek, S.
    Audeh, M. W.
    Weitzel, J. N.
    Friedlander, M.
    Carmichael, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
12345